Improve Understanding of Compounds in Early Phase Oncology Studies

ACR Image Metrix imaging contract research organization (CRO) gave a demonstration of iCAD image analysis software during the 2010 Annual American Society of Clinical Oncology (ASCO) Meeting. This demonstrated that scientists can use novel imaging technology such as DCE-MRI to understand compounds in the early phase oncology studies.

iCAD, a computer-aided detection (CAD) company and an industry leader in providing advanced imaging analysis and workflow solutions to healthcare professionals, partnered with ACR Image Metrix for advanced solutions in DCE-MRI clinical research studies for pharmaceutical and biotechnology companies.

"Partnering with iCAD allows us to offer our sponsors in the oncology drug research arena more advanced solutions to understanding their compounds in the early phase studies using novel imaging modalities such as DCE-MRI," said General Manager of ACR Image Metrix Michael J. Morales. "We found an extremely high level of interest at ASCO and we are pleased iCAD was able to be present at our booth to demonstrate this innovative software technology."

As one of the industry's leading imaging CROs, ACR Image Metrix specializes in providing imaging CRO services to assist pharmaceutical, biotech and medical device companies around the world.